130 related articles for article (PubMed ID: 24867518)
1. Dose-intensive versus dose-control chemotherapy for high-grade osteosarcoma: a meta-analysis.
Wang W; Wang ZC; Shen H; Xie JJ; Lu H
Eur Rev Med Pharmacol Sci; 2014; 18(9):1383-90. PubMed ID: 24867518
[TBL] [Abstract][Full Text] [Related]
2. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.
Tsuchiya H; Tomita K; Mori Y; Asada N; Morinaga T; Kitano S; Yamamoto N
Anticancer Res; 1998; 18(1B):657-66. PubMed ID: 9584049
[TBL] [Abstract][Full Text] [Related]
3. A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.
Jeys LM; Thorne CJ; Parry M; Gaston CL; Sumathi VP; Grimer JR
Clin Orthop Relat Res; 2017 Mar; 475(3):842-850. PubMed ID: 27138473
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
5. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
6. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Bacci G; Ferrari S; Tienghi A; Bertoni F; Mercuri M; Longhi A; Fiorentini G; Forni C; Bacchini P; Rimondini S; De Giorgi U; Picci P
Eur J Surg Oncol; 2001 Feb; 27(1):98-104. PubMed ID: 11237499
[TBL] [Abstract][Full Text] [Related]
7. Response rate as an endpoint in clinical trials.
George SL
J Natl Cancer Inst; 2007 Jan; 99(2):98-9. PubMed ID: 17227987
[No Abstract] [Full Text] [Related]
8. Pathologic fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins.
Xie L; Guo W; Li Y; Ji T; Sun X
J Surg Oncol; 2012 Dec; 106(7):820-5. PubMed ID: 22740310
[TBL] [Abstract][Full Text] [Related]
9. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma.
Zhang FY; Tang W; Zhang ZZ; Huang JC; Zhang SX; Zhao XC
Tumour Biol; 2014 Oct; 35(10):10419-27. PubMed ID: 25053592
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma.
Hundsdoerfer P; Albrecht M; Rühl U; Fengler R; Kulozik AE; Henze G
Eur J Cancer; 2009 Sep; 45(14):2447-51. PubMed ID: 19596190
[TBL] [Abstract][Full Text] [Related]
12. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis.
Pakos EE; Ioannidis JP
Cancer; 2003 Aug; 98(3):581-9. PubMed ID: 12879476
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities.
Machak GN; Tkachev SI; Solovyev YN; Sinyukov PA; Ivanov SM; Kochergina NV; Ryjkov AD; Tepliakov VV; Bokhian BY; Glebovskaya VV
Mayo Clin Proc; 2003 Feb; 78(2):147-55. PubMed ID: 12583525
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Zalupski MM; Rankin C; Ryan JR; Lucas DR; Muler J; Lanier KS; Budd GT; Biermann JS; Meyers FJ; Antman K
Cancer; 2004 Feb; 100(4):818-25. PubMed ID: 14770440
[TBL] [Abstract][Full Text] [Related]
16. [The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum].
Takahashi M; Katagiri H; Sato K; Sugiura H; Yamamura S; Fukaya N; Nakanishi K
Gan To Kagaku Ryoho; 1994 Mar; 21(4):459-64. PubMed ID: 8129386
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
Fan XL; Cai GP; Zhu LL; Ding GM
Drug Des Devel Ther; 2015; 9():5925-32. PubMed ID: 26604690
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].
Zhang Q; Niu XH; Cai YB; Hao L; Ding Y
Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1114-7. PubMed ID: 18005614
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
20. Post operative infection and increased survival in osteosarcoma patients: are they associated?
Jeys LM; Grimer RJ; Carter SR; Tillman RM; Abudu A
Ann Surg Oncol; 2007 Oct; 14(10):2887-95. PubMed ID: 17653803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
